Daiichi Sankyo Honored with Global Impact Award Honorable Mention by the Healthcare Businesswomen’s Association (HBA)
Recognition Highlights Enterprise Leadership, Innovation, and Global Collaboration Driving Impact Across Healthcare and Life Sciences
FAIRFIELD, N.J., 10 February 2026 — The Healthcare Businesswomen’s Association (HBA), a global leadership accelerator, business growth partner, and enterprise solution for the healthcare and life sciences industries, today announced that Daiichi Sankyo has been honored with the Global Impact Award Honorable Mention distinction.
The HBA’s new Global Impact Award is a first-ever organizational honor celebrating companies whose leadership, innovation, collaboration, and business performance drive meaningful and measurable change across healthcare and life sciences. The Honorable Mention distinction recognizes organizations that demonstrate exceptional alignment with the award criteria and deliver impact at scale for patients, the workforce, and healthcare systems across geographies.
“This recognition highlights the power of organizations that lead with intention, invest in leadership, advance innovation with purpose, and collaborate globally to create lasting impact,” said Mary Stutts, CEO of the HBA. “Daiichi Sankyo exemplifies an enterprise-wide commitment to building the future of our industry.”
Daiichi Sankyo will be celebrated during the HBA’s Global Ascension Leadership Experience on 23-24 April 2026 in San Diego, California. Designed for leaders navigating an increasingly complex healthcare landscape, this two-day leadership experience convenes influential voices across biotech, biopharma, medtech, digital health, research, healthcare, and the broader life sciences ecosystem for future-focused ideating, intentional connection, and leadership insight. Registration for the 2026 Leadership Experience is now open.
Global Impact Award Honorable Mention: Daiichi Sankyo
Daiichi Sankyo was recognized with the Global Impact Award Honorable Mention for demonstrating how visionary leadership, scientific innovation, digital capability, and global collaboration can be intentionally aligned to deliver meaningful business results and patient impact at scale. The organization stands out for integrating these elements into a cohesive enterprise strategy that advances healthcare while building a resilient, future-ready workforce.
Central to Daiichi Sankyo’s global impact is an inclusive leadership strategy designed to scale capability across regions, roles, and generations of leaders. Leadership development is embedded within the company’s global People Strategy and anchored in the core behavior of “Develop & Grow.” Through the DS Academy, including the Executive Leadership Accelerator launched in 2024 and the forthcoming Senior Leadership Accelerator in 2026, Daiichi Sankyo has established a structured pathway to strengthen leadership effectiveness throughout the enterprise.
This leadership foundation supports breakthrough scientific innovation with transformative impact on patient outcomes and the oncology landscape. The pioneering DXd antibody drug conjugate platform of Daiichi Sankyo has redefined cancer treatment, with ENHERTU emerging as a breakthrough therapy across multiple tumor types. Approved in more than 85 countries and across seven U.S. indications, ENHERTU has earned 10 FDA Breakthrough Therapy Designations and multiple global awards for clinical impact, reshaping standards of care in breast, lung, gastric, and tumor-agnostic cancers.
Together, these efforts exemplify the intent of the Global Impact Award. By aligning leadership, innovation, and collaboration around a shared purpose, Daiichi Sankyo connects people, performance, and patient impact, positioning the organization as both a high performing enterprise and a defining force shaping the future of global healthcare.
“We are honored that Daiichi Sankyo has received the HBA Global Impact Award Honorable Mention as it underscores our commitment to pioneering science and translating breakthrough research into medicines that improve patient outcomes globally," said Kara Reheis, Vice President of Marketing, Daiichi Sankyo, Inc., and co-Executive Sponsor of the company’s Women’s Forum. "Advancements in science and medicine require exceptional cultures where companies allow their people to continuously learn, develop and grow. We thank the HBA for recognizing these qualities of Daiichi Sankyo.”
Event Details and Contact
For media inquiries, interviews, or information about attending the HBA’s 2026 Global Ascension Leadership Experience, please contact the HBA Marketing and Communications Department at marketing@hbanet.org or visit the event website.
About the Healthcare Businesswomen’s Association (HBA)
The Healthcare Businesswomen’s Association (HBA) is a global leadership accelerator, talent pipeline, and business growth partner for the healthcare industry. With a presence in more than 80 locations, supporting more than 150 Corporate Partners, and impacting nearly six million employees worldwide, the HBA empowers healthcare leaders at every career stage through programs, global forums, and recognition initiatives that celebrate outstanding individuals and organizations. Learn more about the HBA and join our United Force for Change at www.hbanet.org.